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ABSTRACT 
 
Objectives: To assess the cost-effectiveness of laparoscopic surgery compared with 
open surgery for the treatment of colorectal cancer. 
Methods: A Markov model was developed to model cost-effectiveness over 25 years.  
Data on the clinical effectiveness of laparoscopic and open surgery for colorectal 
cancer were obtained from a systematic review of the literature.  Data on costs came 
from a systematic review of economic evaluations and from published sources.  The 
outcomes of the model were presented as the incremental cost per life year gained and 
using cost-effectiveness acceptability curves (CEACs) to illustrate the likelihood that 
a treatment was cost-effective at various threshold values for society’s willingness to 
pay for an additional life year. 
Results: Laparoscopic surgery was on average £300 more costly and slightly less 
effective than open surgery and had a 30% chance of being cost-effective if society is 
willing to pay £30,000 for a life year.  One interpretation of the available data 
suggests equal survival and disease-free survival.  Making this assumption, 
laparoscopic surgery had a greater chance of being considered cost-effective.  
Presenting the results as incremental cost per quality adjusted life year (QALY) made 
no difference to the results, as utility data were poor.  Evidence suggests short-term 
benefits following laparoscopic repair.  This benefit would have to be at least 0.01 of 
a QALY for laparoscopic surgery to be considered cost-effective.  
Conclusions: Laparoscopic surgery is likely to be associated with short-term quality 
of life benefits, similar long-term outcomes and an additional £300 per patient.  A 
judgement is required as to whether the short-term benefits are worth this extra cost.   
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INTRODUCTION 
Colorectal cancer is one of the most common cancers in the Western world.  In the 
United Kingdom (UK), it is the second most common cancer in women and the third 
most common cancer in men.   
 
Colorectal cancer cases typically arise sporadically in individuals over the age of 50 
(12), with only a small proportion of patients having a strong inherited predisposition.  
Further risk factors relate to diet, bodyweight, physical exercise, tobacco and alcohol 
consumption (4).   
 
Surgical resection of the cancer is the main treatment and is almost always performed 
as an open surgical procedure.  Open resection involves one long incision through the 
abdominal wall and is associated with high complication rates.  These complications 
include wound infection, post-operative pain, anastomotic leakage, urinary tract 
infection and long-term complications such as incisional hernia.  Some of the main 
disadvantages of open resection include incisional pain and an often lengthy 
hospitalisation.  Laparoscopic surgery, a minimally invasive approach, might provide 
an alternative.  Compared with open surgery it is believed to offer short-term quality 
of life benefits (12).  Concerns over its longer-term effectiveness and cost, however, 
have led to a slow up-take.  Furthermore, laparoscopic surgery is technically more 
complicated to perform and its success may be influenced by the experience of the 
surgical team.   
 
Laparoscopic surgery involves several small incisions to the abdominal wall, in which 
ports are inserted, allowing the surgical instruments to be manipulated.  A variant is 
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laparoscopically-assisted resection where the bowel is accessed laparoscopically but 
then a port site incision is enlarged which allows the excision of the disease.  
Anastomosis is then performed externally.  In practical terms, laparoscopic and 
laparoscopically-assisted resections can be considered comparable as the incision 
sizes are relatively similar (hereafter they are collectively known as laparoscopic 
surgery).    
 
This study estimated the relative cost-effectiveness of laparoscopic compared with 
open surgery for the treatment of colorectal cancer as well as exploring the cost-
effectiveness of the different modes of surgery by stage of disease.   
 
METHODS 
Markov Model 
A Markov model was constructed to estimate the long-term costs and benefits of a 
cohort of typical patients for the alternative surgical treatments (Figure 1).  The model 
followed a cohort of patients from initial operation through convalescence (operation 
state) to return to usual activities (‘disease-free’ state).  The patients may remain in 
this state until they die or they suffer a recurrence or metastasis and therefore have a 
re-operation or some other form of management.  Theoretically, the patients could 
move between states until they all eventually die.  For the purposes of the analysis, 
the cohort of patients have been modelled for a maximum of 25 years (the likely 
maximum survival for the majority of patients).  The cycle length was set at six 
months. 
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The main cost components included in the model were the initial operative procedure 
and the costs of subsequent re-operations or management.  If a recurrence occurred 
and a re-operation indicated, the patient is assumed to receive an open procedure.  
Death is the only state within the model that a patient cannot leave (it is an absorbing 
state).   
 
The short-term surgical complications were principally captured through increased 
operating times and longer hospitalisation.  The risk of an emergency re-operation 
within the first few weeks after surgery was explicitly modelled due to the additional 
operation costs incurred.  Similarly, where the cost of managing other complications 
were not captured through increased operating time and length of stay, their 
probability of occurrence and cost was factored into the cost of a state. 
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Derivation of Model Parameters of Clinical Effectiveness 
The strongest source of data required for each parameter in the model were derived 
from a systematic review of randomised controlled trials (RCTs) of the two 
interventions in the treatment of colorectal cancer (12).  Data on mortality, recurrence 
rates, re-operation rates, emergency operations and the long-term risk of hernia were 
all taken from this review (12).  In brief, this review, an update of a previous review 
conducted in 2000 (20), involved a systematic literature search, restricted to the years 
2000 onwards.  Full details of the search strategy are available from the authors (12).  
All included studies needed to meet pre-specified eligibility criteria.  Standard meta-
analysis techniques were used to obtain overall estimates of effectiveness, where 
appropriate, and are reported in detail elsewhere (12).  The review included a total of 
46 reports describing 20 studies (19 RCTs and one individual patient data (IPD) meta-
analysis).  The IPD meta-analysis (2), synthesised data from a subset of patients from 
four of the main RCTs included within the systematic review of effectiveness; (6, 7, 
9, 19).  
 
The risk of death and recurrence were taken from the IPD meta-analysis (2) and were 
assigned a constant rate based on consideration of the survival curves which showed a 
similar rate, for both interventions (See Table 1 for parameter values used in the 
model).  The risk of mortality following the recurrence of non-operative cancer was 
based on data derived from Benoist and colleagues (1).  A beta distribution was used 
to reflect the uncertainty in this estimate.  Other baseline parameters required for the 
model included the risk of: hernia, emergency re-operation for a post-operative 
complication; and re-operation for recurrent disease.  The risk of hernia was identified 
as an important long-term complication.  The severity and rates of port site hernia and 
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incisional hernia were included in the model.  As data were sparse it was not possible 
to draw any distinction between the two types of hernia.  The rate of hernia for open 
resection was derived from the rates reported in the open arms of those trials (10, 21) 
identified by the systematic review of effectiveness and a further focused search of 
non-randomised studies (5, 18).  The risk of hernia per cycle was estimated for each 
study and the median of these was used.  A triangular distribution based on the 
estimated 25 and 75 percentile estimates from the identified studies was used (Table 
1). 
 
It was believed that the risk of emergency surgery for most post-operative 
complications would be low.  The one complication for which an emergency re-
operation would generally be required was anastomotic leakage and, based on clinical 
advice, the risk of an emergency re-operation was taken to be equal to the risk of an 
anastomotic leakage (personal communication: Professor Z Krukowski and Ms A 
McKinley, 2005).  The baseline risk of an anastomotic leakage was based on the rates 
reported in the open arms of those trials identified by the systematic review of 
effectiveness (12).  The point estimate and distribution were defined using the same 
method as described above.   
 
Should the cancer recur the individual might have a re-operation but data on this were 
not available from any of the included studies.  Data from Grampian University 
Hospitals NHS Trust, however, suggested that out of over 300 resections per year, 
approximately 14 to 15 are re-operations (personal communication: Professor Z 
Krukowski and Ms A McKinley, 2005).  A beta distribution was used to reflect 
uncertainty of the point estimate.   
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 Data on relative effect sizes of laparoscopic versus open surgery were derived from 
the systematic review of effectiveness (12) and the IPD meta-analysis (2).  The 
relative effect size of the risk of death and recurrence for laparoscopic versus open 
resection were based on the interpretation of the IPD meta-analysis (2) to provide an 
estimate of the relative difference between laparoscopic and open surgery.  A normal 
distribution was defined using information on the confidence interval surrounding the 
relative difference. 
 
A relative risk of one was assumed for the mortality rate for individuals with non-
curative cancer as prognosis was taken to be the same regardless of the initial method 
of resection (Table 1).  The relative risk of an emergency operation was based on that 
for anastomotic leakage, which came from the systematic review of effectiveness 
(12).  Based on the confidence interval reported, a lognormal distribution was used to 
define the imprecision around this estimate. (Table 1). 
 
The relative risk of hernia and the relative risk of a re-operation following a 
recurrence were also required.  In both cases a relative risk of one was assumed.  In 
the former case the evidence from the review of effectiveness was limited but there 
was no statistically significant difference between the rates of both types of hernia 
(12).  In the latter case this was because the initial method of resection would not 
affect the method of management subsequent to a recurrence.   
 
Data on Resource Use and Cost 
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Total costs included initial operation costs, hospital ward costs and any further 
follow-up costs.  The analysis was taken from a UK NHS perspective and focussed on 
direct medical costs.  Table 1 shows the estimated costs for laparoscopic and open 
resection.  These costs were derived using data based on a UK RCT comparing 
laparoscopic with open surgery within an enhanced recovery programme (8).  The 
follow-up costs from this RCT were only up to three months and related to a fast-
track recovery programme. They do not, therefore, reflect typical length of stay 
estimates.  These data, therefore, were combined with more typical estimates of 
length of stay and post-operative complications from the systematic review of 
effectiveness (12) to estimate the operation cost incurred in the first six months (i.e. 
the first cycle of the model).  Added to this cost were the costs of follow-up visits, 
based on consultation with clinical experts to reflect the frequency of visits.  Costs of 
two potential complications were also modelled (risk of emergency surgery and risk 
of incisional or port-site hernia).  The cost per patient was the product of the 
probability of those complications occurring, combined with standard UK unit costs 
(16).  The cost of care for those patients suffering a recurrence where re-operation 
would not be indicated was the cost of medications used to control symptoms.  These 
were based on a typical drug regime of care for a patient, defined following 
consultation with a MacMillan Cancer Nurse (personal communication: Flora O’Dea 
– Hospital Specialist Palliative Care Team 2005) (3).   
 
Cost-effectiveness 
The base-case analysis was based on the costs and outcomes faced by a cohort of 
typical patients.  Results are presented as incremental cost per additional life year 
gained.  The data are also presented as cost effectiveness acceptability curves 
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(CEACs), which reflect the statistical variability in the model’s input parameters.  
These curves illustrate the likelihood that a strategy is cost-effective at various 
threshold values for society’s willingness to pay for an additional life year.  All costs 
and benefits were discounted, at a rate of 6% for costs and 1.5% for benefits (13).  
Costs were based on 2004 prices and the analysis was conducted from the perspective 
of the UK NHS. 
 
Sensitivity analysis 
In addition to the probabilistic sensitivity analysis used to generate CEACs, sensitivity 
analysis focused on varying key assumptions and/or parameters in the base-case 
model.  Sensitivity analyses surrounding the relative survival and disease-free 
survival estimates for laparoscopic resection were performed, as they are important 
drivers within the model and subject to considerable uncertainty.  To further evaluate 
these estimates, a second analysis using alternative survival and disease-free survival 
estimates for both open and laparoscopic patients, based on the meta-analysis of all 
relevant trials was conducted (12).  These estimates were manipulated to allow the 
mortality and recurrence rates for laparoscopic compared with open resection to be 
established giving point estimates of 0.97 (standard deviation of 0.03) and 0.99 
(standard deviation of 0.03) respectively.  Given the nature of the data, the 
imprecision around the relative risk was assigned a normal distribution.  Further 
analysis also considered the use of various quality of life estimates to estimate quality 
adjusted life years (QALYs).  Sensitivity analyses surrounding the base-line risk of 
hernia, mortality rates for patients with non-operative cancer and rates of re-operation 
following recurrence were also conducted.      
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RESULTS 
Base-case and equal survival 
For the base-case model, laparoscopic is dominated by open resection over the 25-
year time horizon; that is laparoscopic resection is more costly and less effective in 
comparison to open resection (Table 2).  One interpretation of the data provided by 
the IPD meta-analysis, however, is that there is no difference between laparoscopic 
and open resection in terms of survival and disease-free survival at three years (2).  
An analysis assuming equal survival and disease-free survival showed that 
laparoscopic resection was, again, more costly and no more effective (Table 2).  
Based on these data alone it would be unlikely that a policy maker would recommend 
increasing the uptake of laparoscopic surgery.  The point estimates of the incremental 
cost-effectiveness provided do not, however, provide any indication of the uncertainty 
that surrounds the model parameters.   
 
Figures 2 and 3 report the CEACs comparing laparoscopic to open surgery in terms of 
life years for the base-case model and for the equal survival analysis.  Open surgery 
has a greater chance of being considered cost-effective, for the base-case analysis, at 
the various threshold values of society’s willingness to pay for a life year.  If society 
was willing to pay £30,000 for a life year then laparoscopic resection has 
approximately a 30% chance of being considered cost-effective (Figure 2).  The 
results are driven by very small differences in survival and disease-free survival 
estimated to exist at three years follow-up.  Therefore, an alternative interpretation of 
the data on survival and disease-free survival is that there are no meaningful 
differences and, in this situation, the likelihood that laparoscopic surgery might be 
considered cost-effective is greater compared with the base-case analysis (Figure 3).   
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Sensitivity analysis 
Using the two pooled estimates derived for overall survival and disease-free survival 
from the meta-analysis resulted in laparoscopic surgery being more costly (by 
approximately £350) but more effective, with an incremental cost-effectiveness ratio 
(ICER) of £1778 (Table 2 and Figure 4).  This result is as would be expected given 
the pooled estimates on survival and disease-free survival used (12).  This analysis 
serves to highlight the sensitivity of the model to these particular parameter estimates. 
 
Utility data, though sparse, were sought in an attempt to capture the quality of life 
differences that might be apparent following the two forms of resection.  Data were 
taken from one published study using the EQ-5D questionnaire to obtain utility scores 
(17).  Based on these data it has been assumed that the recovery from both open and 
laparoscopic surgery was associated with a value of 0.83.  It has also been assumed 
that, by definition, the time spent free from disease was associated with a value of 1.  
The value associated with the other states (except death) was also 0.83.  These utility 
estimates were applied to the base-case model.  Both the deterministic and 
probabilistic analyses are similar to the base-case results (See Table 2).   
 
The estimates of QALYs do not capture any potential QALY gain that might be 
associated with an earlier recovery following laparoscopic surgery.  Some indication 
of the relevance of this was assessed by looking at the QALY gain required for 
laparoscopic surgery to be judged worthwhile.  Assuming a threshold value for 
society’s willingness to pay for a QALY of £30,000 (14), and given the mean 
incremental cost of laparoscopic surgery of £289, then the implied value of the QALY 
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gain would need to be 0.010 QALYs (approximately three and a half days in full 
health). 
 
The results from much of the other sensitivity analyses were similar to the base-case 
results.  The model was, however, highly sensitive to changes in the relative effect 
sizes associated with non-operable cancer mortality and re-operation rates but there is 
no evidence to suggest that the management of patients would differ between the 
comparators.  Finally consideration was given to the effect of stage of disease on the 
results using data presented in the IPD meta-analysis (2).  Results were broadly 
similar to the base-case analysis, though there was considerable uncertainty 
surrounding parameter estimates.  Further evidence on these outcomes, therefore, is 
warranted. 
 
DISCUSSION 
It is likely that laparoscopic and open resection are similar in terms of long-term 
survival and disease-free survival.  It is also likely that laparoscopic resection has 
some short-term advantages in terms of recovery in the postoperative period (12).  
When the cost-effectiveness measure was presented in terms of either cost per life 
year or QALY, laparoscopic surgery was, on average, dominated by open surgery.  
These results reflect the very small differences in overall survival that were apparent 
at three years and also the lack of available utility data in which to gauge the impact 
of earlier recovery following laparoscopic surgery.  The results would be greatly 
strengthened if longer term randomised data were available.  With respect to utilities, 
the data available to estimate QALYs were meagre and should be treated with 
extreme caution.  Further work in this area is warranted to determine just what level 
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of QALY gain might be apparent following a shorter post-operative recovery and in 
the long-term.  The importance of this can be ascertained from the fact that only a 
0.01 gain in QALYs would be necessary for laparoscopic surgery to be considered 
cost-effective at a £30,000 threshold.  It is quite plausible that a gain of this 
magnitude might exist when it is noted that in a comparison between laparoscopic and 
open groin hernia repair, the observed QALY gain was 0.006 (11).   
 
Sensitivity analyses were performed to determine the effect of changing assumptions 
around the input parameters of the economic model.  In doing so the probability that 
laparoscopic surgery might be considered cost-effective ranged from 30% to 80%.  
The analysis where laparoscopic surgery had an 80% chance of being considered cost-
effective was when the base-case survival and disease-free survival estimates were 
replaced with the pooled estimates taken from the systematic review of effectiveness 
(12).  It should be noted, however, that this pooled analysis does not take account of 
any potential differential timing of events. 
 
There was little information on long-term wound related morbidities such as hernias.  
It is likely that the types of hernias and subsequently the costs, management and risk 
of hernia would also be different following both forms of resection.  Because of the 
lack of data, however, the cost, management and associated risks were assumed to be 
the same for both forms of surgery.  A sensitivity analysis that addressed the impact 
of this assumption showed little impact on results.  Similarly in relation to all costs, 
little data were available.  With respect to the main component of costs (the initial 
operation), these were based on data from a very small UK RCT (8).   Further cost 
data from a larger sample would be beneficial.   
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 One important event associated with laparoscopic surgery that was not modelled 
explicitly, owing to a lack of useable data, was the effect of conversion.  Laparoscopic 
patients might be converted to open surgery for various reasons.  Often these patients 
have worse outcomes than those not converted (12).  It is unclear, however, whether 
patients converted to open surgery would have experienced similar complications 
regardless of which form of surgery had first been undertaken (i.e. they were 
inappropriately considered eligible for laparoscopic surgery).  The effects of 
conversion also relate to the level of experience of the particular surgeon and their 
team.  Less experienced surgeons and surgical teams might be expected to have a 
higher rate of conversion than those who are more experienced.  The level of 
conversion (and hence cost-effectiveness) is likely, therefore, to be determined not 
only by appropriate patient selection but also by operator experience.   
 
The results were sensitive to changes in the assumption that care for recurrent disease 
would be the same for both forms of surgery.  There is, however, no evidence to 
suggest that the management would differ between surgeries.  Should new data 
emerge indicating this then further work to develop this aspect of the model would be 
warranted. 
 
A subgroup analysis focusing on stage of disease was also conducted.  Its results were 
based on very meagre data and are unreliable.  Other subgroups that would be 
relevant to investigate are age, gender and cancer site though it was not possible to 
incorporate these outcomes into the model owing to a lack of useable data.  Further 
analysis and research for these sub-groups is warranted. 
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 CONCLUSION 
This paper has explored the cost-effectiveness of laparoscopic surgery for colorectal 
cancer.  This study is the first economic evaluation, using a Markov model to predict 
long-term outcomes, to be conducted within this area.  Laparoscopic surgery is more 
costly and has a likelihood of being considered cost-effective of between 30% to 80% 
depending on the assumptions made.  The implied valuation conducted found that, 
assuming a willingness to pay threshold of £30,000, laparoscopic surgery would need 
to be associated with a QALY gain of 0.01 in order to be considered cost-effective. 
 
Further data is required relating to utility values to assess QALYs, longer term data 
with regards to survival and disease-free survival, evidence relating to relevant 
subgroups and on the risk and value of ‘secondary’ outcomes such as hernias.  
 
POLICY IMPLICATIONS  
A judgement must be made as to whether the guidelines on open surgery should 
change.  Currently, less than 1% of all colorectal cancer surgeries are performed 
laparoscopically.  Given the evidence that laparoscopic surgery appears to have 
similar long-term outcomes compared to open surgery, as well as being associated 
with potential short-term benefits, there is a case to increase the current level of 
service provision.  On the basis of evidence presented in this paper, and other 
evidence, the National Institute for Health and Clinical Excellence recommended that 
laparoscopic surgery is an acceptable method of surgery for colorectal cancer in the 
UK (15).   
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Very few surgeons or surgical teams are trained in this particular form of surgery and 
the implications for training of increasing the number of laparoscopic resections 
performed needs to be considered.  Any decision that might be taken by policy 
makers with regards to this, however, must take into consideration the extra costs 
associated with laparoscopic resection and indeed whether the probable quality of life 
gains are worth this increased cost. 
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Table 1 All parameters used within the model 
 
Parameter Value 
Distribution and values used 
to define distributions Source 
Baseline probabilities per cycle 
(six months)    
Mortality 0.03 No distribution Bonjer (2) 
Recurrence 0.046 No distribution Bonjer (2) 
Mortality (non-operative 
cancer) 0.2 Beta: α =5.4, β=21.6 Benoist (1) 
Emergency operation rate 0.019 Tri: IQR 0.008 to 0.034 Murray (12) 
Risk of hernia 0.03 Tri: IQR 0.002 to 0.012 
Winslow (21), Leung 
(10), Patankar (18), 
Champult (5) 
Re-operation rate (after 
recurrence) 0.05 Beta: α =15, b=285 NHS Grampian 
Relative effect sizes    
Mortality 1.016 Normal: 95% CI 0.958 to 1.054 Bonjer (2) 
Recurrence 0.993 Normal: 95% CI 0.943 to 1.060 Bonjer (2) 
Mortality (non-operative 
cancer) 1 None Benoist (1) 
Emergency operation rate 1.13 Lognormal: 0.74 to 1.73 
MA from SR of  
Effectiveness (12) 
Risk of hernia 1 None  
Re-operation rate (after 
recurrence) 1 None  
Costs (£) 2004    
Open procedure cost including 
follow-up to 3 months 5,852 Tri: IQR 4968 to 6272 King (8) 
Relative cost of laparoscopic 1.05 Log normal: SD 0.33 King (8) 
Emergency operation 1,615 Tri: IQR 1130 to 2322 NRC HRG F42 (16)
Re-operation (as open) 5,852 Tri: IQR 4968 to 6272 King (8) 
Outpatient visit 99 None King (8) 
CT scan 73 Tri: IQR 56 to 91 NRC, CT (other) (16)
Colonoscopy 622 Tri: IQR 370 to 868 NRC HRG F35 (16)
Surgery for hernia 1,689 Tri: IQR 1306 to 2234 NRC HRG F72 (16)
Non-operative management 
following recurrence 1,216 None 
Expert advice; Costs 
from BNF (3) 
Utilities (QALYs)    
Initial operation 0.83 None Norum (17) 
Disease-free 1 None  
Recurrence 0.83 None Norum (17) 
Disease-free (after recurrence) 1 None  
Non-operative management 0.83 None Norum (17) 
Dead 0 None  
 
Tri = Triangular distribution; IQR = Interquartile range; MA = Meta-analysis; SR = Systematic review; CI = 
Confidence interval; SD = Standard deviation; NRC = National Reference Costs; HRG = Health Related Group; 
CT = Computed tomography; BNF = British National Formulary; QALYs = Quality Adjusted Life Years  
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Table 2 Base-case and sensitivity analysis results (deterministic and probabilistic) 
 
 Probability of cost-effectiveness for different 
threshold values for society's willingness to 
pay for a Life Year (%) 
Base-case and sensitivity analysis  Procedure Cost (£) 
2004 
Life 
years 
ICER (£) 
£10,000 £20,000 £30,000 £50,000 
Open 10174 15.351   61.6% 66.4% 67.6% 67.7% Base-case 
Laparoscopic 
 
 
 
 
 
 10463 
 
15.298 
 
Dominated 
 
38.4% 
 
33.6% 
 
32.4% 
 
32.3% 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RR = Relative risk; OS = Overall survival; DFS = Disease-free survival; MA = Meta-analysis; ICER = Incremental cost effectiveness ratio; QALYs = Quality adjusted life years 
 
Open 
 
10174 15.351   54.7% 54.8% 54.9% 54.2% Equal Survival 
Laparoscopic 
 
10490 
 
15.351 
 
Dominated 
 
45.3% 
 
45.2% 
 
45.1% 
 
45.8% 
 
Open 10174 15.351   26.7% 20.4% 18.6% 18.0% RR for OS and DFS from  
MA conducted as part of the  
systematic review of  
effectiveness (12) 
Laparoscopic 
 
10511 
 
15.541 
 
1778 
 
73.3% 
 
79.6% 
 
81.4% 
 
82.0% 
 
Probability of cost-effectiveness for different 
threshold values for society's willingness to 
pay for a QALY (%) 
Sensitivity analysis  Procedure Cost (£) 
2004 
QALYs ICER (£) 
£10,000 £20,000 £30,000 £50,000 
Open 
 
10174 14.679   61.0% 65.1% 65.7% 66.7% Use of utility values to estimate 
QALYs (17) 
Laparoscopic 10463 14.630 Dominated 39.0% 34.9% 34.3% 33.3% 
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Figure 1 Model structure 
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Figure 2 Cost-effectiveness acceptability curve showing society’s 
willingness to pay for a life year for the comparison of 
laparoscopic with open surgery (Base-case analysis) 
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Figure 3 Cost-effectiveness acceptability curve showing society’s 
willingness to pay for a life year for the comparison of 
laparoscopic with open surgery assuming equal survival and 
disease-free survival  
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Figure 4 Cost-effectiveness acceptability curve showing society’s 
willingness to pay for a life year for the comparison of 
laparoscopic with open surgery using pooled estimates of 
survival and disease-free survival from the systematic review 
of effectiveness (12)  
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